High expression of L-GILZ transcript variant 1 (GILZ TV 1) is associated with increased 30-day sepsis mortality, and a high expression ratio possibly contraindicates hydrocortisone administration.
GILZ
GILZ Transcript variant
Glucocorticoid-induced leucine zipper
Hydrocortisone
Mortality
Sepsis
TSC22D3
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
12 Aug 2024
12 Aug 2024
Historique:
received:
17
05
2024
accepted:
05
08
2024
medline:
13
8
2024
pubmed:
13
8
2024
entrez:
12
8
2024
Statut:
epublish
Résumé
Sepsis presents a challenge due to its complex immune responses, where balance between inflammation and anti-inflammation is critical for survival. Glucocorticoid-induced leucine zipper (GILZ) is key protein in achieving this balance, suppressing inflammation and mediating glucocorticoid response. This study aims to investigate GILZ transcript variants in sepsis patients and explore their potential for patient stratification and optimizing glucocorticoid therapy. Sepsis patients meeting the criteria outlined in Sepsis-3 were enrolled, and RNA was isolated from whole blood samples. Quantitative mRNA expression of GILZ transcript variants in both sepsis patient samples (n = 121) and the monocytic U937 cell line (n = 3), treated with hydrocortisone and lipopolysaccharides, was assessed using quantitative PCR (qPCR). Elevated expression of GILZ transcript variant 1 (GILZ TV 1) serves as a marker for heightened 30-day mortality in septic patients. Increased levels of GILZ TV 1 within the initial day of sepsis onset are associated with a 2.2-[95% CI 1.2-4.3] fold rise in mortality, escalating to an 8.5-[95% CI 2.0-36.4] fold increase by day eight. GILZ TV1 expression is enhanced by glucocorticoids in cell culture but remains unaffected by inflammatory stimuli such as LPS. In septic patients, GILZ TV 1 expression increases over the course of sepsis and in response to hydrocortisone treatment. Furthermore, a high expression ratio of transcript variant 1 relative to all GILZ mRNA TVs correlates with a 2.3-fold higher mortality rate in patients receiving hydrocortisone treatment. High expression of GILZ TV 1 is associated with a higher 30-day sepsis mortality rate. Moreover, a high expression ratio of GILZ TV 1 relative to all GILZ transcript variants is a parameter for identifying patient subgroups in which hydrocortisone may be contraindicated.
Sections du résumé
BACKGROUND
BACKGROUND
Sepsis presents a challenge due to its complex immune responses, where balance between inflammation and anti-inflammation is critical for survival. Glucocorticoid-induced leucine zipper (GILZ) is key protein in achieving this balance, suppressing inflammation and mediating glucocorticoid response. This study aims to investigate GILZ transcript variants in sepsis patients and explore their potential for patient stratification and optimizing glucocorticoid therapy.
METHODS
METHODS
Sepsis patients meeting the criteria outlined in Sepsis-3 were enrolled, and RNA was isolated from whole blood samples. Quantitative mRNA expression of GILZ transcript variants in both sepsis patient samples (n = 121) and the monocytic U937 cell line (n = 3), treated with hydrocortisone and lipopolysaccharides, was assessed using quantitative PCR (qPCR).
RESULTS
RESULTS
Elevated expression of GILZ transcript variant 1 (GILZ TV 1) serves as a marker for heightened 30-day mortality in septic patients. Increased levels of GILZ TV 1 within the initial day of sepsis onset are associated with a 2.2-[95% CI 1.2-4.3] fold rise in mortality, escalating to an 8.5-[95% CI 2.0-36.4] fold increase by day eight. GILZ TV1 expression is enhanced by glucocorticoids in cell culture but remains unaffected by inflammatory stimuli such as LPS. In septic patients, GILZ TV 1 expression increases over the course of sepsis and in response to hydrocortisone treatment. Furthermore, a high expression ratio of transcript variant 1 relative to all GILZ mRNA TVs correlates with a 2.3-fold higher mortality rate in patients receiving hydrocortisone treatment.
CONCLUSION
CONCLUSIONS
High expression of GILZ TV 1 is associated with a higher 30-day sepsis mortality rate. Moreover, a high expression ratio of GILZ TV 1 relative to all GILZ transcript variants is a parameter for identifying patient subgroups in which hydrocortisone may be contraindicated.
Identifiants
pubmed: 39135180
doi: 10.1186/s13054-024-05056-1
pii: 10.1186/s13054-024-05056-1
doi:
Substances chimiques
Hydrocortisone
WI4X0X7BPJ
TSC22D3 protein, human
0
Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
270Informations de copyright
© 2024. The Author(s).
Références
Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med. 2008;14:64–78.
doi: 10.2119/2007-00102.Monneret
pubmed: 18026569
pmcid: 2078557
Arens C, Bajwa SA, Koch C, Siegler BH, Schneck E, Hecker A, Weiterer S, Lichtenstern C, Weigand MA, Uhle F. Sepsis-induced long-term immune paralysis–results of a descriptive, explorative study. Crit Care. 2016;20:93.
doi: 10.1186/s13054-016-1233-5
pubmed: 27056672
pmcid: 4823837
Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862–74.
doi: 10.1038/nri3552
pubmed: 24232462
pmcid: 4077177
Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity. 2014;40:463–75.
doi: 10.1016/j.immuni.2014.04.001
pubmed: 24745331
Giamarellos-Bourboulis EJ, Aschenbrenner AC, Bauer M, Bock C, Calandra T, Gat-Viks I, Kyriazopoulou E, Lupse M, Monneret G, Pickkers P, Schultze JL, van der Poll T, et al. The pathophysiology of sepsis and precision-medicine-based immunotherapy. Nat Immunol. 2024;25:19–28.
doi: 10.1038/s41590-023-01660-5
pubmed: 38168953
Xu C, Xu J, Lu L, Tian W, Ma J, Wu M. Identification of key genes and novel immune infiltration-associated biomarkers of sepsis. Innate Immun. 2020;26:666–82.
doi: 10.1177/1753425920966380
pubmed: 33100122
pmcid: 7787554
Bereshchenko O, Coppo M, Bruscoli S, Biagioli M, Cimino M, Frammartino T, Sorcini D, Venanzi A, Sante M, Riccardi C. GILZ promotes production of peripherally induced treg cells and mediates the crosstalk between glucocorticoids and TGF-β signaling. Cell Rep. 2014;7:464–75.
doi: 10.1016/j.celrep.2014.03.004
pubmed: 24703841
Ronchetti S, Migliorati G, Riccardi C. GILZ as a Mediator of the Anti-Inflammatory Effects of Glucocorticoids. Front Endocrinol. 2015;6:170.
doi: 10.3389/fendo.2015.00170
Ballegeer M, Vandewalle J, Eggermont M, van Isterdael G, Dejager L, de Bus L, Decruyenaere J, Vandenbroucke RE, Libert C. Overexpression of Gilz protects mice against lethal septic peritonitis. Shock. 2019;52:208–14.
doi: 10.1097/SHK.0000000000001252
pubmed: 30124596
Ellouze M, Vigouroux L, Tcherakian C, Woerther P-L, Guguin A, Robert O, Surenaud M, Tran T, Calmette J, Barbin T, Perlemuter G, Cassard A-M, et al. Overexpression of GILZ in macrophages limits systemic inflammation while increasing bacterial clearance in sepsis in mice. Eur J Immunol. 2020;50:589–602.
doi: 10.1002/eji.201948278
pubmed: 31840802
Bruscoli S, Riccardi C, Ronchetti S. GILZ as a regulator of cell fate and inflammation. Cells. 2021;11:122.
doi: 10.3390/cells11010122
pubmed: 35011684
pmcid: 8750894
Ayroldi E, Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J. 2009;23:3649–58.
doi: 10.1096/fj.09-134684
pubmed: 19567371
Spiga F, Walker JJ, Terry JR, Lightman SL (2014) HPA axis-rhythms. In: Comprehensive physiology, 1273–1298
Soundararajan R, Wang J, Melters D, Pearce D. Differential activities of glucocorticoid-induced leucine zipper protein isoforms. J Biol Chem. 2007;282:36303–13.
doi: 10.1074/jbc.M707287200
pubmed: 17956870
Ayroldi E, Petrillo MG, Bastianelli A, Marchetti MC, Ronchetti S, Nocentini G, Ricciotti L, Cannarile L, Riccardi C. L-GILZ binds p53 and MDM2 and suppresses tumor growth through p53 activation in human cancer cells. Cell Death Differ. 2015;22:118–30.
doi: 10.1038/cdd.2014.129
pubmed: 25168242
Bruscoli S, Velardi E, Di Sante M, Bereshchenko O, Venanzi A, Coppo M, Berno V, Mameli MG, Colella R, Cavaliere A, Riccardi C. Long glucocorticoid-induced leucine zipper (L-GILZ) protein interacts with ras protein pathway and contributes to spermatogenesis control. J Biol Chem. 2012;287:1242–51.
doi: 10.1074/jbc.M111.316372
pubmed: 22110132
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche J-D, Coopersmith CM, Hotchkiss RS, Levy MM, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.
doi: 10.1001/jama.2016.0287
pubmed: 26903338
pmcid: 4968574
Unterberg M, Ehrentraut SF, Bracht T, Wolf A, Haberl H, von Busch A, Rump K, Ziehe D, Bazzi M, Thon P, Sitek B, Marcus K, et al. Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis. Crit Care. 2023;27:417.
doi: 10.1186/s13054-023-04713-1
pubmed: 37907989
pmcid: 10619294
Palmowski L, Nowak H, Witowski A, Koos B, Wolf A, Weber M, Kleefisch D, Unterberg M, Haberl H, von Busch A, Ertmer C, Zarbock A, et al. Assessing SOFA score trajectories in sepsis using machine learning: a pragmatic approach to improve the accuracy of mortality prediction. PLoS ONE. 2024;19: e0300739.
doi: 10.1371/journal.pone.0300739
pubmed: 38547245
pmcid: 10977876
Ziehe D, Marko B, Thon P, Rahmel T, Palmowski L, Nowak H, von Busch A, Wolf A, Witowski A, Vonheder J, Ellger B, Wappler F, et al. The aquaporin 3 polymorphism (rs17553719) is associated with sepsis survival and correlated with IL-33 secretion. Int J Mol Sci. 2024;25:1400.
doi: 10.3390/ijms25031400
pubmed: 38338680
pmcid: 10855683
Hoppstädter J, Diesel B, Eifler LK, Schmid T, Brüne B, Kiemer AK. Glucocorticoid-induced leucine zipper is downregulated in human alveolar macrophages upon Toll-like receptor activation. Eur J Immunol. 2012;42:1282–93.
doi: 10.1002/eji.201142081
pubmed: 22539300
TSC22D3 (5-Mar-2024) (retrieved on 08.05.2024). https://www.ncbi.nlm.nih.gov/gene/1831
Di Marco B, Massetti M, Bruscoli S, Macchiarulo A, Di Virgilio R, Velardi E, Donato V, Migliorati G, Riccardi C. Glucocorticoid-induced leucine zipper (GILZ)/NF-kappaB interaction: role of GILZ homo-dimerization and C-terminal domain. Nucleic Acids Res. 2007;35:517–28.
doi: 10.1093/nar/gkl1080
pubmed: 17169985
Ayroldi E, Petrillo MG, Marchetti MC, Cannarile L, Ronchetti S, Ricci E, Cari L, Avenia N, Moretti S, Puxeddu E, Riccardi C. Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation. Cell Death Dis. 2018;9:305.
doi: 10.1038/s41419-018-0346-y
pubmed: 29467389
pmcid: 5833869
Mittelstadt PR, Ashwell JD. Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ. J Biol Chem. 2001;276:29603–10.
doi: 10.1074/jbc.M101522200
pubmed: 11397794
Ayroldi E, Zollo O, Macchiarulo A, Di Marco B, Marchetti C, Riccardi C. Glucocorticoid-induced leucine zipper inhibits the Raf-extracellular signal-regulated kinase pathway by binding to Raf-1. Mol Cell Biol. 2002;22:7929–41.
doi: 10.1128/MCB.22.22.7929-7941.2002
pubmed: 12391160
pmcid: 134721
Roskoski R. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res. 2012;66:105–43.
doi: 10.1016/j.phrs.2012.04.005
pubmed: 22569528
Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci. 2004;117:5965–73.
doi: 10.1242/jcs.01589
pubmed: 15564374
Healy ZR, Zhu F, Stull JD, Konstantopoulos K. Elucidation of the signaling network of COX-2 induction in sheared chondrocytes: COX-2 is induced via a Rac/MEKK1/MKK7/JNK2/c-Jun-C/EBPβ-dependent pathway. Am J Physiol Cell Physiol. 2008;294:C1146–57.
doi: 10.1152/ajpcell.00542.2007
pubmed: 18367585
Hoppstädter J, Kiemer AK. Glucocorticoid-induced leucine zipper (GILZ) in immuno suppression: master regulator or bystander? Oncotarget. 2015;6:38446–57.
doi: 10.18632/oncotarget.6197
pubmed: 26498359
pmcid: 4770713
Shalova IN, Lim JY, Chittezhath M, Zinkernagel AS, Beasley F, Hernández-Jiménez E, Toledano V, Cubillos-Zapata C, Rapisarda A, Chen J, Duan K, Yang H, et al. Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1α. Immunity. 2015;42:484–98.
doi: 10.1016/j.immuni.2015.02.001
pubmed: 25746953
Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, Reinke P, Volk H-D. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression. Am J Respir Crit Care Med. 2009;180:640–8.
doi: 10.1164/rccm.200903-0363OC
pubmed: 19590022
Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13:260–8.
doi: 10.1016/S1473-3099(13)70001-X
pubmed: 23427891
pmcid: 3798159
Otto GP, Sossdorf M, Claus RA, Rödel J, Menge K, Reinhart K, Bauer M, Riedemann NC. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care. 2011;15:R183.
doi: 10.1186/cc10332
pubmed: 21798063
pmcid: 3387626
Tang BM, Herwanto V, McLean AS. Immune paralysis in sepsis: recent insights and future development. In: Vincent J-L, editor. Annual update in intensive care and emergency medicine 2018. Cham: Springer; 2018. p. 13–23.
doi: 10.1007/978-3-319-73670-9_2
van den Berghe G, Téblick A, Langouche L, Gunst J. The hypothalamus-pituitary-adrenal axis in sepsis- and hyperinflammation-induced critical illness: gaps in current knowledge and future translational research directions. EBioMedicine. 2022;84:104284.
doi: 10.1016/j.ebiom.2022.104284
pubmed: 36162206
pmcid: 9519475
Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre P-F, Reinhart K, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358:111–24.
doi: 10.1056/NEJMoa071366
pubmed: 18184957
Antcliffe DB, Burnham KL, Al-Beidh F, Santhakumaran S, Brett SJ, Hinds CJ, Ashby D, Knight JC, Gordon AC. Transcriptomic signatures in sepsis and a differential response to steroids. From the VANISH randomized trial. Am J Respir Crit Care Med. 2018;199:980–6.
doi: 10.1164/rccm.201807-1419OC
König R, Kolte A, Ahlers O, Oswald M, Krauss V, Roell D, Sommerfeld O, Dimopoulos G, Tsangaris I, Antoniadou E, Jaishankar N, Bogatsch H, et al. Use of IFNγ/IL10 ratio for stratification of hydrocortisone therapy in patients with septic shock. Front Immunol. 2021;12: 607217.
doi: 10.3389/fimmu.2021.607217
pubmed: 33767693
pmcid: 7985546
Schäfer ST, Gessner S, Scherag A, Rump K, Frey UH, Siffert W, Westendorf AM, Steinmann J, Peters J, Adamzik M. Hydrocortisone fails to abolish NF-κB1 protein nuclear translocation in deletion allele carriers of the NFKB1 promoter polymorphism (-94ins/delATTG) and is associated with increased 30-day mortality in septic shock. PLoS ONE. 2014;9: e104953.
doi: 10.1371/journal.pone.0104953
pubmed: 25133403
pmcid: 4136840
Zhang S, Chang W, Xie J, Wu Z, Yang Y, Qiu H. The efficacy, safety, and optimal regimen of corticosteroids in sepsis: a Bayesian network meta-analysis. Crit Care Explor. 2020;2: e0094.
doi: 10.1097/CCE.0000000000000094
pubmed: 32426736
pmcid: 7188436
Choi K, Park JE, Kim A, Hwang S, Bae J, Shin TG, Kim K. The DEXA-SEPSIS study protocol: a phase II randomized double-blinded controlled trial of the effect of early dexamethasone in high-risk sepsis patients. Clin Exp Emerg Med. 2022;9:246–52.
doi: 10.15441/ceem.22.276
pubmed: 36116775
pmcid: 9561197